Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Keyphrases

• Novel Agents 100%
• Hematological Malignancies 100%
• Recent Update 100%
• Chimeric Antigen Receptor T Cells (CAR-T) 50%
• Isocitrate Dehydrogenase 1 (IDH1) 50%
• Clinical Trials 25%
• New York 25%
• B-cell Lymphoma 2 (Bcl-2) 25%
• Cell-to-cell 25%
• Small Molecule Inhibitors 25%
• Bruton's Tyrosine Kinase 25%
• Oncology 25%
• Oncoprotein 25%
• Oncologists 25%
• Chinese Americans 25%
• Immunotherapeutics 25%
• Hematologist 25%
• Janus Kinase 2 (JAK2) 25%
• Cancer Immunotherapy 25%
• Antibody-antigen 25%
• Free Agent 25%
• BCR-ABL 25%
• FMS-like Tyrosine Kinase 3 (FLT3) 25%

Medicine and Dentistry

• Hematologic Malignancy 100%
• Hematology 100%
• T Cell 50%
• Chimeric Antigen Receptor 50%
• Biological Marker 25%
• Clinical Trial 25%
• Oncology 25%
• Oncologist 25%
• Janus Kinase 25%
• Oncoprotein 25%
• Bruton Tyrosine Kinase 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Hematologic Malignancy 100%
• Chimeric Antigen Receptor 50%
• Biological Marker 25%
• Malignant Neoplasm 25%
• Clinical Trial 25%
• Chemotherapy 25%
• Immunotherapy 25%
• Oncoprotein 25%
• Janus Kinase 25%
• Bruton Tyrosine Kinase 25%